[ CAS No. 1228014-10-5 ] {[proInfo.proName]}

Name: 1228014-10-5|5-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-2-(2-((trimethylsilyl)oxy)propan-2-yl)pyridine|98%
Brand: Ambeed
SKU: A290314
Price: 19.0 USD
Availability: InStock
Rating: 90 (25 reviews)

,{[proInfo.pro_purity]}

Cat. No.: {[proInfo.prAm]}

2D 3D

Structure of 1228014-10-5 * Storage: {[proInfo.prStorage]}

Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Search after Editing

* Storage: {[proInfo.prStorage]}

For Research Only 110K+ Compounds Competitive Price 1-2 Day Shipping

Quality Control of [ 1228014-10-5 ]

COA NMR CNMR HPLC LC-MS

Related Doc. of [ 1228014-10-5 ]

SDS Specification

Alternatived Products of [ 1228014-10-5 ]

Product Details of [ 1228014-10-5 ]

CAS No. :	1228014-10-5	MDL No. :	MFCD12198135
Formula :	C₁₇H₃₀BNO₃Si	Boiling Point :	-
Linear Structure Formula :	-	InChI Key :	GQSLZAFZAPLKEY-UHFFFAOYSA-N
M.W :	335.32	Pubchem ID :	53398358
Synonyms :

Calculated chemistry of [ 1228014-10-5 ]

Physicochemical Properties

Num. heavy atoms :	23
Num. arom. heavy atoms :	6
Fraction Csp3 :	0.71
Num. rotatable bonds :	4
Num. H-bond acceptors :	4.0
Num. H-bond donors :	0.0
Molar Refractivity :	98.55
TPSA :	40.58 Å²

Pharmacokinetics

GI absorption :	High
BBB permeant :	Yes
P-gp substrate :	Yes
CYP1A2 inhibitor :	No
CYP2C19 inhibitor :	No
CYP2C9 inhibitor :	No
CYP2D6 inhibitor :	Yes
CYP3A4 inhibitor :	Yes
Log Kp (skin permeation) :	-5.83 cm/s

Lipophilicity

Log Po/w (iLOGP) :	0.0
Log Po/w (XLOGP3) :	3.54
Log Po/w (WLOGP) :	3.36
Log Po/w (MLOGP) :	1.3
Log Po/w (SILICOS-IT) :	1.44
Consensus Log Po/w :	1.93

Druglikeness

Lipinski :	0.0
Ghose :	None
Veber :	0.0
Egan :	0.0
Muegge :	0.0
Bioavailability Score :	0.55

Water Solubility

Log S (ESOL) :	-4.08
Solubility :	0.028 mg/ml ; 0.0000835 mol/l
Class :	Moderately soluble
Log S (Ali) :	-4.08
Solubility :	0.0281 mg/ml ; 0.0000838 mol/l
Class :	Moderately soluble
Log S (SILICOS-IT) :	-5.42
Solubility :	0.00127 mg/ml ; 0.00000378 mol/l
Class :	Moderately soluble

Medicinal Chemistry

PAINS :	0.0 alert
Brenk :	1.0 alert
Leadlikeness :	1.0
Synthetic accessibility :	3.84

Safety of [ 1228014-10-5 ]

Signal Word:	Warning	Class:	N/A
Precautionary Statements:	P261-P305+P351+P338	UN#:	N/A
Hazard Statements:	H302-H315-H319-H335	Packing Group:	N/A
GHS Pictogram:

Application In Synthesis of [ 1228014-10-5 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Upstream synthesis route of [ 1228014-10-5 ]
Downstream synthetic route of [ 1228014-10-5 ]

[ 1228014-10-5 ] Synthesis Path-Upstream 1~3

1
[ 73183-34-3 ]
[ 1228014-10-5 ]

Yield	Reaction Conditions	Operation in experiment
80%	With dichloro(1,1'-bis(diphenylphosphanyl)ferrocene)palladium(II)*CH₂Cl₂; potassium acetate In 1,4-dioxane at 80 - 100℃; for 2 h; Inert atmosphere; Sealed tube	5-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-2-{2-[(trimethylsilyl)oxy]propan-2-yl}pyridine In a pressure tube, a stirring solution of Intermediate 146 (200 mg, 0.69 mmol) in 1,4-dioxane (8 mL) was treated with bis(pinacolato)diboron (211 mg, 0.83 mmol) and potassium acetate (205 mg, 2.09 mmol). The stirring mixture was degassed with nitrogen for 10 minutes, then Pd(dppf)Cl₂ complex with DCM (29 mg, 0.04 mmol) was added. The pressure tube was sealed and the contents were stirred at 80° C. for 1 h, then at 100° C. for 1 h. The reaction mixture was allowed to cool and then filtered through celite, washing with ethyl acetate (30 mL). The filtrate was concentrated under vacuum to give a dark brown oil, which was triturated in 2:1 ether:heptane (10 mL). The suspension was filtered and the filtrate concentrated in vacuo to give a brown oil which was loaded onto a 10 g HP-silica cartridge and eluted on a Biotage Isolera 4, from a 0-100percent ethyl acetate in heptanes gradient, to afford the title compound (185 mg, 80percent) as a light brown solid. δ_H (500 MHz, CDCl₃) 8.85 (s, 1H), 8.03 (d, J 7.8 Hz, 1H), 7.64 (d, J 7.9 Hz, 1H), 1.61 (s, 6H), 1.34 (s, 12H), 0.14 (s, 9H).

Reference： [1] Patent: US2015/152065, 2015, A1, . Location in patent: Paragraph 0641

2
[ 624-28-2 ]
[ 1228014-10-5 ]

Reference： [1] Patent: US2015/152065, 2015, A1,

3
[ 290307-40-3 ]
[ 1228014-10-5 ]

Reference： [1] Patent: US2015/152065, 2015, A1,

[ 1228014-10-5 ] Synthesis Path-Downstream 1~15

1
[ 1228014-10-5 ]
7-bromo-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one [ No CAS ]
7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((1r,4r)-4-methoxycyclohexyl)-3,4-dihydropyrazino-[2,3-b]pyrazin-2(1H)-one [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
93%	With sodium carbonate;PdCl2(AmPhos)3; In N,N-dimethyl-formamide; at 70℃; for 1.5h;	Ethyl 2-(3,5-dibromopyrazin-2-ylamino)acetate (1 equiv) and trans-4- methoxycyclohexanamine.hydrochloride (1.5 equiv), NMP and DIEA were combined and heated to 127 0C and maintained at that temperature for 18 h. Upon reaction completion, the mixture was cooled to 35 0C over 4 h. The batch was transferred to a mixture of ethyl acetate and 5 % brine. The aqueous layer was removed and the organic layer containing the batch was washed successively with 5 % brine and water. The organic layer containing the batch was concentrated by vacuum distillation to a low volume, cooled to ambient temperature and the solids were collected by vacuum filtration. The filter cake was washed with MTBE and the product was dried in a vacuum to give 41% yield of ethyl 2-(5-bromo- 3-(trans-4-methoxycyclohexylamino)pyrazin-2-ylamino) acetate. A mixture of ethyl 2-(5- bromo-3-(trans-4-methoxycyclohexylamino)pyrazin-2-ylamino) acetate (1 equiv), water and 85 % phosphoric acid (3:1) was heated to 80 0C over 1 h. Heating was maintained for 18 h to effect reaction completion. Upon reaction completion, the mixture was cooled to 25 0C and filtered to give a crude product as tan solid. The resulting solids were washed with water, slurried in water and filtered. The filter cake was washed with water until the pH of the filtrate was between 4 and 8. The resulting material was dried under vacuum to give 89 % yield of 7-bromo-l-(trans-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin- 2(lH)-one. 7-Bromo-l-(trans-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin- 2(lH)-one (1 equiv), 5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-2-(2- (trimethylsilyloxy)propan-2-yl)pyridine (1 equiv), sodium carbonate (3 equiv) and PdCl2(AmPhOs)2 (0.003 equiv) were combined in isopropanol and heated at 70 0C for 1.5 h. Standard work-up and purification afforded the protected compound in 93 % yield. Deprotection using standard conditions for removal of a trimethylsilyl-group and isolation gave the title compound.

Reference： [1]Patent: WO2010/62571,2010,A1 .Location in patent: Page/Page column 107-108

2
[ 1228014-10-5 ]
6-bromo-1-[2-(difluoromethoxy)benzyl]-5-fluoro-2-methyl-1H-benzimidazole [ No CAS ]
{1-[5-(1-[2-(difluoromethoxy)phenyl]methyl}-5-fluoro-2-methylbenzimidazol-6-yl)-pyridin-2-yl]-1-methylethoxy}(trimethyl)silane [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
71%	With dichloro(1,1'-bis(diphenylphosphanyl)ferrocene)palladium(II)*CH2Cl2; potassium carbonate; In 1,4-dioxane; water; at 100℃; for 7h;Inert atmosphere;	{1-[5-(1-[2-(Difluoromethoxy)phenyl]methyl}-5-fluoro-2-methylbenzimidazol-6-yl)-pyridin-2-yl]-1-methylethoxy}(trimethyl)silane Intermediate 147 (185 mg, 0.55 mmol) and Intermediate 50 (175 mg, 0.45 mmol) were dissolved in anhydrous 1,4-dioxane (8 mL) and 2M aqueous potassium carbonate solution (0.7 mL) was added. The mixture was degassed under nitrogen for 5 minutes. Pd(dppf)Cl2 complex with DCM (20 mg, 0.024 mmol) was added. The mixture was stirred at 100 C. under nitrogen for 7 h. The reaction mixture was allowed to cool, dried over sodium sulfate and concentrated under vacuum to give crude product as a dark oil (318 mg). This material was loaded onto a 10 g HP-silica cartridge and eluted on a Biotage Isolera 4, from a 0-70% ethyl acetate in heptane gradient, to afford the title compound (166 mg, 71%) as a colourless oil. deltaH (500 MHz, CDCl3) 8.61 (s, 1H), 7.85 (d, J 8.0 Hz, 1H), 7.72 (d, J 8.2 Hz, 1H), 7.53 (d, J 10.8 Hz, 1H), 7.37-7.29 (m, 1H), 7.21-7.14 (m, 2H), 7.13-7.06 (m, 1H), 6.80-6.45 (m, 2H), 5.43-5.37 (m, 2H), 2.61 (s, 3H), 1.65 (s, 6H), 0.17 (s, 9H).

Reference： [1]Patent: US2015/152065,2015,A1 .Location in patent: Paragraph 0642

3
5-bromo-2-{2-[(trimethylsilyl)oxy]propan-2-yl}pyridine [ No CAS ]
[ 73183-34-3 ]
[ 1228014-10-5 ]

Yield	Reaction Conditions	Operation in experiment
80%	With dichloro(1,1'-bis(diphenylphosphanyl)ferrocene)palladium(II)*CH2Cl2; potassium acetate; In 1,4-dioxane; at 80 - 100℃; for 2h;Inert atmosphere; Sealed tube;	5-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-2-{2-[(trimethylsilyl)oxy]propan-2-yl}pyridine In a pressure tube, a stirring solution of Intermediate 146 (200 mg, 0.69 mmol) in 1,4-dioxane (8 mL) was treated with bis(pinacolato)diboron (211 mg, 0.83 mmol) and potassium acetate (205 mg, 2.09 mmol). The stirring mixture was degassed with nitrogen for 10 minutes, then Pd(dppf)Cl2 complex with DCM (29 mg, 0.04 mmol) was added. The pressure tube was sealed and the contents were stirred at 80 C. for 1 h, then at 100 C. for 1 h. The reaction mixture was allowed to cool and then filtered through celite, washing with ethyl acetate (30 mL). The filtrate was concentrated under vacuum to give a dark brown oil, which was triturated in 2:1 ether:heptane (10 mL). The suspension was filtered and the filtrate concentrated in vacuo to give a brown oil which was loaded onto a 10 g HP-silica cartridge and eluted on a Biotage Isolera 4, from a 0-100% ethyl acetate in heptanes gradient, to afford the title compound (185 mg, 80%) as a light brown solid. deltaH (500 MHz, CDCl3) 8.85 (s, 1H), 8.03 (d, J 7.8 Hz, 1H), 7.64 (d, J 7.9 Hz, 1H), 1.61 (s, 6H), 1.34 (s, 12H), 0.14 (s, 9H).

Reference： [1]Patent: US2015/152065,2015,A1 .Location in patent: Paragraph 0641

4
[ 624-28-2 ]
[ 1228014-10-5 ]

Reference： [1]Patent: US2015/152065,2015,A1

5
[ 290307-40-3 ]
[ 1228014-10-5 ]

Reference： [1]Patent: US2015/152065,2015,A1

6
[ 1228014-10-5 ]
2-[5-(1-[2-(difluoromethoxy)phenyl]methyl}-5-fluoro-2-methylbenzimidazol-6-yl)-pyridin-2-yl]propan-2-ol [ No CAS ]

Reference： [1]Patent: US2015/152065,2015,A1

7
[ 1228014-10-5 ]
4-[(6-bromo-2-methylimidazo[1,2-a]pyridin-3-yl)methyl]-8-fluoro-3,4-dihydro-2H-1,4-benzoxazin-3-one [ No CAS ]
8-fluoro-4-({6-[6-(2-hydroxypropan-2-yl)pyridin-3-yl]-2-methylimidazo[1,2-a]pyridin-3-yl}methyl)-3,4-dihydro-2H-1,4-benzoxazin-3-one [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
		General procedure: Prepared from Intermediate 21 and 5 -(4,4,5,5 -tetramethyl- 1,3 ,2-dioxaborolan-2- yl)-2- {2- [(trimethylsilyl)oxy]propan-2-yl} pyridine by a method analogous to that used to prepare Example 1, followed by treatment with TBAF at room temperature. H (500MHz, DMSO-d6) 8.82 (d,J2.2 Hz, 1H), 8.75 (s, 1H), 8.04 (dd,J8.3, 2.4 Hz, 1H), 7.78(d,J8.2 Hz, 1H), 7.63 (dd,J9.3, 1.7 Hz, 1H), 7.57 (d,J9.3 Hz, 1H), 7.19 (d,J8.3 Hz,1H), 7.06 (td,J8.3, 5.7 Hz, 1H), 7.00 (t,J8.7 Hz, 1H), 5.64 (s, 2H), 5.31 (s, 1H), 4.88 (s,2H), 2.39 (s, 3H), 1.50 (s, 6H). LCMS m/z 447.

Reference： [1]Patent: WO2015/86506,2015,A1 .Location in patent: Page/Page column 191

8
[ 1228014-10-5 ]
(4-{4-bromo-5-[(4-chlorophenyl)sulfanyl]-1,3-oxazol-2-yl}cyclohexyl)methanol [ No CAS ]
2-(5-{5-[(4-chlorophenyl)sulfanyl]-2-[cis-4-(hydroxymethyl)cyclohexyl]-1,3-oxazol-4-yl}pyridin-2-yl)propan-2-ol [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
		Example B5.18 2-(5-{5-[(4-Chlorophenyl)sulfanyl]-2-[cis-4-(hydroxymethyl)cyclohexyl]-1,3-oxazol-4-yl}pyridin-2-yl)propan-2-olTo a mixture of bromide (43.0 mg, 0.107 mmol), <strong>[1228014-10-5]5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-{2-[(trimethylsilyl)oxy]propan-2-yl}pyridine</strong> (40.5 mg, 0.160 mmol), tetrakis(triphenylphosphine)palladium(0) (12.3 mg, 10.7 mumol) in toluene (2000 mul) was added K2CO3 (267 mul, 0.534 mmol) and heated in oil bath at 120 C. for 12 h. The reaction was diluted with CH2Cl2, dried over Na2SO4, filtered and conc. The residue was dissolved in THF (1 mL) and treated with TBAF (107 mul, 0.107 mmol) for 1 h. The solvent was removed and the residue was purified by reverse-phase HPLC (C-18, 20-80% MeCN in H2O, with 0.05% TFA) to provide product as a white solid. 1H NMR (CDCl3, 400 MHz) delta 9.37 (s, 1H), 8.86-8.82 (m, 1H), 7.72 (d, J=8.8 Hz, 1H), 7.31-7.27 (m, 2H), 7.22-7.19 (m, 2H), 4.24 (d, 6.0 Hz, 1H), 3.54 (d, J=6.0 Hz, 1H), 2.87-2.78 (m, 1H), 2.27-2.20 (m, 2H), 2.00-1.96 (m, 2H), 1.71 (s, 6H), 1.70-1.43 (m, 3H), 1.26-1.09 (m, 2H). FIRMS (ES) [M+1]+ calcd for C24H28ClN2O3S: 459.1504. Found: 459.1498.

Reference： [1]Patent: US9193697,2015,B2 .Location in patent: Page/Page column 65; 66

9
[ 1228014-10-5 ]
5-[(4-chlorophenyl)sulfanyl]-2-(tetrahydro-2H-pyran-4-yl)-1,3-oxazole [ No CAS ]
2-(5-{5-[(4-chlorophenyl)sulfanyl]-2-(tetrahydro-2H-pyran-4-yl)-1,3-oxazol-4-yl}pyridin-2-yl)propan-2-ol [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
		Example B5.12-(5-{5-[(4-Chlorophenyl)sulfanyl]-2-(tetrahydro-2H-pyran-4-yl)-1,3-oxazol-4-yl}pyridin-2-yl)propan-2-olTo a mixture of B5 (540 mg, 1.44 mmol), tetrakis(triphenylphosphine)palladium(0) (83.0 mg, 0.0720 mmol), and <strong>[1228014-10-5]5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-{2-[(trimethylsilyl)oxy]propan-2-yl}pyridine</strong> (438 mg, 1.73 mmol) in toluene (11.5 mL) was added 2.0 M aqueous solution of K2CO3 (2.2 mL). The resulting mixture was heated at 160 C. in a microwave for 1 h. The process was repeated three more times until the starting material consumed. The reaction mixture was diluted with dichloromethane, dried over Na2SO4 and filtered. The filtrate was concentrated and dissolved in THF (10.7 mL) and treated with TBAF (1.1 mL, 1M in THF) at room temperature for 1 h. The solvent was removed and the residue was purified by silica gel flash chromatography (5-70% EtOAc in hexanes), followed by reverse-phase HPLC (C-18, 20-90% MeCN in H2O, with 0.05% TFA) and a final purification by silica gel flash chromatography (10-70% EtOAc in hexanes) to provide the title compound as a clear oil. The product turned into a white solid after converting to the HCl salt foam. 1H NMR (CDCl3, 400 MHz) delta 9.18 (dd, J=1.2, 2.0, Hz, 1H), 8.33 (dd, J=2.0, 8.4 Hz, 1H), 7.42 (dd, J=1.2, 8.4 Hz, 1H), 7.29-7.238 (m, 2H), 7.16-7.13 (m, 2H), 4.85 (s, 1H), 4.06 (td, J=3.6, 8.4 Hz, 2H), 3.55 (dt, J=3.2, 10.8 Hz, 2H), 3.12 (m, 1H), 2.07-1.94 (m, 4H), 1.56 (s, 6H). HRMS (ES) [M+1]+ calcd for C22H24ClN2O3S: 431.1191. Found: 431.1198.

Reference： [1]Patent: US9193697,2015,B2 .Location in patent: Page/Page column 61; 62

10
[ 1228014-10-5 ]
(7R,14R)-11-chloro-1-(difluoromethoxy)-10-fluoro-6,7-dihydro-7,14-methanobenzimidazo[1,2-b][2,5]benzodiazocin-5(14H)-one [ No CAS ]
(7R,14R)-1-(difluoromethoxy)-10-fluoro-11-[6-(2-hydroxypropan-2-yl)pyridin-3-yl]-6,7-dihydro-7,14-methanobenzimidazo[1,2-b][2,5]benzodiazocin-5 (14H)-one [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
38%	With potassium phosphate; tris-(dibenzylideneacetone)dipalladium(0); tricyclohexylphosphine tetrafluoroborate; In 1,4-dioxane; water; at 20 - 105℃; for 1h;	A degassed mixture of Example 10 (299 mg, 0.56 mmol), 6-(2-(trimethylsilyloxy)propan- 2-yl)pyridine-3-boronic acid pinacol ester (295 mg, 0.84 mmol),tris(dibenzylideneacetone)dipalladium(0) (26.0 mg, 0.03 mmo 1), potassium phosphate tribasic (296 mg, 1.40 mmol), and tricyclohexylphosphonium tetrafluoroborate (26.0 mg, 0.07 mmol) in 1,4-dioxane (4.5 mL) and water (0.5 mL) was heated to 105 C overnight. The reaction mixture was cooled to r.t, diluted with EtOAc (50 mL) and washed with water (2 x 50 mL). The organic layer was dried (Na2SO4), filtered and concentrated invacuo. The residues were dissolved in DCM (4 mL) and 4M HC1 solution (1.5 mL) was added. The solution was stirred at r.t for 1 hour. Saturated aqueous sodium carbonate solution (50 mL) was added, and the aqueous layer separated. The organic layer was washed with brine (50 mL), dried (Na2504), filtered and concentrated in vacuo to give a crude oil. The crude material was purified by column chromatography, eluting with 0-100% EtOAc in DCM, followed by 0-10% MeOH in EtOAc to give the title compound as an off-white powder (105 mg, 38% yield).1H NMR (400 MHz, DMSO) oe 9.15 (d, 1 H, J = 6.8 Hz), 8.61 (s, 1 H), 8.26-8.21 (m, 1 H), 7.90 (dt, 1 H, J = 1.9, 8.2 Hz), 7.77 (d, 1 H, J= 8.2 Hz), 7.61 (t, 1 H, J = 75 Hz), 7.61 (d, 1 H, J 11.5 Hz), 7.52-7.50 (m, 3 H), 6.34 (d, 1 H, J 7.1 Hz), 5.27 (s, 1 H), 4.91 (t,1 H, J = 6.8 Hz), 3.52-3.45 (m, 1 H), 2.75 (d, 1 H, J = 13.4 Hz), 1.49 (s, 6 H). LCMS Method 3 ESI MH+ 495.1

Reference： [1]Patent: WO2016/50975,2016,A1 .Location in patent: Page/Page column 248; 249

11
[ 1228014-10-5 ]
(7R,14R)-11-chloro-1-(difluoromethoxy)-6,7-dihydro-7,14-methanobenzimidazo[1,2-b][2,5]benzodiazocin-5(14H)-one [ No CAS ]
(7R,14R)-1-(difluoromethoxy)-11-[6-(2-trimethylsilyloxypropan-2-yl)pyridin-3-yl]-6,7-dihydro-7,14-methanobenzimidazo[1,2-b][2,5]benzodiazocin-5(14H)-one [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
96%	With tris-(dibenzylideneacetone)dipalladium(0); tricyclohexylphosphine tetrafluoroborate; In 1,4-dioxane; water; at 105℃;Inert atmosphere;	Example 11 (750 mg, 2.00 mmol), 6-(2-(trimethylsilyloxy)propan-2-yl)pyridine-3- boronic acid pinacol ester (1.41 g, 4.00 mmol), tris(dibenzylideneacetone)dipalladium(0) (94 mg, 0.1 mmol) and tricyclohexylphosphonium tetrafluoroborate (91 mg, 0.24 mmol,97 mass%) were added to a round bottom flask, evacuated & refilled with nitrogen and1 ,4-dioxane (10 mL) added followed by potassium phosphate (1.27 g, 6.00 mmol) in water (1 mL). The mixture was degassed, placed under nitrogen and heated to 105C overnight. The mixture was partitioned between EtOAc and water, the organic layer dried over sodium sulphate, filtered and concentrated in vacuo. The crude material was purifiedby chromatography, (EtOAc to 15% MeOH gradient). The product fractions were concentrated in vacuo to give the title compound as an off-white solid, (1.05 g, 96% yield). LC/MS Method 3: RT 1.61 minutes, mlz 549.

Reference： [1]Patent: WO2016/50975,2016,A1 .Location in patent: Page/Page column 198

12
[ 1228014-10-5 ]
(7R,14R)-11-chloro-1-(difluoromethoxy)-6,7-dihydro-7,14-methanobenzimidazo[1,2-b][2,5]benzodiazocin-5(14H)-one [ No CAS ]
(7R,14R)-1-(difluoromethoxy)-11-[6-(2-hydroxypropan-2-yl)pyridin-3-yl]-6,7-dihydro-7,14-methanobenzimidazo[1,2-b][2,5]benzodiazocin-5 (14H)-one [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
20%	With potassium phosphate; tris-(dibenzylideneacetone)dipalladium(0); tricyclohexylphosphine tetrafluoroborate; In 1,4-dioxane; water; at 105℃; for 18h;Microwave irradiation;	Example 11 (140 mg, 0.373 mmol) and 6-(2-(trimethylsilyloxy)propan-2-yl)pyridine-3- boronic acid pinacol ester (171 mg, 0.484 mmol) were added to a small microwave tube and tris(dibenzylideneacetone)dipalladium(0) (17.6 mg, 0.0 186 mmol) and tricyclohexylphosphonium tetrafluoroborate (17.0 mg, 0.0447 mmol) were added withdioxane (2 mL), followed by K3P04 (158 mg, 0.745 mmol) in water (1 mL). The mixture was degassed and heated to 105C for 18 hours. The mixture was diluted with EtOAc (30 mL) and washed with water (10 mL). The organic was concentrated in vacuo, redissolved in DCM (10 mL) and 4.OM HC1 in dioxane (5 mL) added and the mixture was stirred at r.t for 1 hour. The mixture was partitioned between DCM and sodium carbonate(20 mL). The organic phase was dried (Na2SO4), filtered and concentrated in vacuo.Purification by preparative HPLC gave the title compound (35 mg, 20%) as a white solid.1HNMR: (d6-DMSO 300 MHz) oe:1.48 (s, 6 H), 2.74 (d, 1H, J=13.3 Hz), 3.49 (m, 1H),4.88 (t, 1H, J=6.7 Hz), 5.24 (s, 1H), 6.35 (d, 1H, J7.0 Hz), 7.49-7.53 (m, 3H), 7.69-7.72(m, 3H), 7.66 (t, 1H, JHF73.2Hz), 7.97 (dd, 1H, J = 5.6, 8.2 Hz), 8.21-8.24 (m, 1H),8.73 (d, 1H, J 1.8 Hz), 9.13 (d, 1H, 6.8 Hz). LC/MS Method 3: RT 1.76 mins (pH 10),mlz 477.

Reference： [1]Patent: WO2016/50975,2016,A1 .Location in patent: Page/Page column 250; 251

13
[ 1228014-10-5 ]
7-chloro-1-isopropyl-N-[(6-methyl-2-oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl]imidazo[1,5-a]pyridine-5-carboxamide [ No CAS ]
1-isopropyl-N-[(6-methyl-2-oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl]-7-(6-{2-[(trimethylsilyl)oxy]propan-2-yl}pyridin-3-yl)imidazo[1,5-a]pyridine-5-carboxamide [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With potassium phosphate; chloro(2-dicyclohexylphosphino-2?,6?-diisopropoxy-1,1?-biphenyl)[2-(2?-amino-1,1?-biphenyl)]palladium(II) 2nd generation; In tetrahydrofuran; at 50℃; for 2h;Inert atmosphere;	To a solution of 7-chloro- 1 -isopropyl-N- [(6-methyl-2-oxo-4-propyl- 1 ,2-dihydropyridin-3- yl)methyl]imidazo[1,5-a]pyridine-5-carboxamide (intermediate 202A) (250 mg, 0.62 mmol) and 5-(4,4,5,5-tetramethyl- 1 ,3,2-dioxaborolan-2-yl)-2- { 2- [(trimethylsilyl)oxy]propan-2-yl }pyridine (241 mg, 0.75 mmol) in tetrahydrofuran (10 ml) under an atmosphere of nitrogen was added potassium phosphate (0.5 M, 4.2 ml), followed by a solution of (2?-aminobiphenyl-2- yl)(chloro)dicyclohexyl(2?,6?-diisopropoxybiphenyl-2-yl)palladium (2? generation Ruphos precatalyst) (98 mg, 125 mmol) in tetrahydrofuran (0.5 ml), and the reaction was stirred at 50 Cfor 2 h. Water was added, the phases were separated and the aqueous phase was extracted with ethyl acetate. The combined organic phases were washed with brine, dried over sodium sulfate and concentrated in vacuo. The residue was taken to the next step without purification.LCMS (conditions 2.4): Rt 1.40 mm; MS (ESI): [M + H] = 574.5.

Reference： [1]Patent: WO2016/102493,2016,A1 .Location in patent: Page/Page column 194; 195

14
[ 1228014-10-5 ]
iupleE [ No CAS ]
8-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-N-(6-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyridin-2-yl)-5-oxo-1,2,3,5-tetrahydroindolizine-6-carboxamide [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
25%	With (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride; water; sodium carbonate; In 1,4-dioxane; at 85℃; for 16h;Inert atmosphere;	[0570] A mixture of crude Example 122c (150 mg, 0.3 mmol), Example d (100 mg, 0.3 mmol), Pd(dppf)Cl2 (23 mg, 0.03 mmol) and Na2C03 (100 mg, 0.9 mmol) in Dioxane/H20(3 mL/1 mL) was exchange N2 for 3 times. After stirred at 85C for 16 h at N2, the mixture was concentrated under reduced pressure, which was purified by Pre-TLC (Petroleum DCM/MeOH = 10/1) to give Example 126 38 mg, yield 25%) as a yellow solid. LCMS [M+l] + = 500. [0571] 1H NMR (400 MHz, DMSO-d 6) delta 12.59 (s, 1H), 8.88 (s, 1H), 8.60 (d, J= 2.4 Hz, 1H), 8.48 (s, 1H), 8.36 (d, J= 8.3 Hz, 1H), 8.01 (t, J= 8.0 Hz, 1H), 7.90 (dd, J= 8.2, 2.4 Hz, 1H), 7.81 (d, J= 7.5 Hz, 1H), 7.74 (d, J= 8.2 Hz, 1H), 5.35-5.28(m,lH), 5.27 (s, 1H), 4.26 (t,J= 7.4 Hz, 2H), 3.34 (d, J= 2.7 Hz, 2H), 2.29 - 2.03 (m, 2H), 1.52 (d, J= 6.7 Hz, 6H), 1.46 (s, 6H).

Reference： [1]Patent: WO2018/151830,2018,A1 .Location in patent: Paragraph 0570-0571

15
[ 1228014-10-5 ]
C₁₇H₁₇IN₆O₂ [ No CAS ]
C₂₈H₃₅N₇O₃Si [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
34.26 mg	With (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride; sodium carbonate; In 1,4-dioxane; water; at 80℃;Inert atmosphere;	[0435] A mixture of Example 66a (50 mg, 0.11 mmol), Example 66b (43.1 mg, 0.13 mmol) in Dioxane/H20 (2mL, 10: 1) was added Pd(dppf)Cl2 (5 mg, 0.0068 mmol) and Na2C03(34.26 mg, 0.33 mmol). Then the mixture was degassed by bubbling N2 through the solution for 2 min using a syringe needle. After that, the mixture was heated at 80Covernight. LCMS [M+l]+ = 546.1

Reference： [1]Patent: WO2018/151830,2018,A1 .Location in patent: Paragraph 0435

Same Skeleton Products

Related Products

Historical Records

Related Functional Groups of
[ 1228014-10-5 ]

Organoboron

[ 1300118-52-8 ]

2-(5-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)propan-2-ol

Similarity: 0.86

Esters

[ 1300118-52-8 ]

2-(5-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)propan-2-ol

Similarity: 0.86

[ 1441765-57-6 ]

2-(5-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)propan-2-ol hydrochloride

Similarity: 0.85

[ 2246720-37-4 ]

2-(4-Methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)propan-2-ol

Similarity: 0.81

Ghs Precautionary Statements

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Purity	Size	Price	VIP Price	USA Stock *0-1 Day	Global Stock *5-7 Days	Quantity
{[ item.p_purity ]}	{[ item.pr_size ]}	{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]}	{[ getRatePrice(item.pr_usd, 1,1) ]}	Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]}	{[ item.pr_usastock ]}	Inquiry -	{[ item.pr_chinastock ]}	Inquiry -

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed
H304	May be fatal if swallowed and enters airways
H305	May be harmful if swallowed and enters airways
H310	Fatal in contact with skin
H311	Toxic in contact with skin
H312	Harmful in contact with skin
H313	May be harmful in contact with skin
H314	Causes severe skin burns and eye damage
H315	Causes skin irritation
H316	Causes mild skin irritation
H317	May cause an allergic skin reaction
H318	Causes serious eye damage
H319	Causes serious eye irritation
H320	Causes eye irritation
H330	Fatal if inhaled
H331	Toxic if inhaled
H332	Harmful if inhaled
H333	May be harmful if inhaled
H334	May cause allergy or asthma symptoms or breathing difficulties if inhaled
H335	May cause respiratory irritation
H336	May cause drowsiness or dizziness
H340	May cause genetic defects
H341	Suspected of causing genetic defects
H350	May cause cancer
H351	Suspected of causing cancer
H360	May damage fertility or the unborn child
H361	Suspected of damaging fertility or the unborn child
H361d	Suspected of damaging the unborn child
H362	May cause harm to breast-fed children
H370	Causes damage to organs
H371	May cause damage to organs
H372	Causes damage to organs through prolonged or repeated exposure
H373	May cause damage to organs through prolonged or repeated exposure
Environmental hazards
Code	Phrase
H400	Very toxic to aquatic life
H401	Toxic to aquatic life
H402	Harmful to aquatic life
H410	Very toxic to aquatic life with long-lasting effects
H411	Toxic to aquatic life with long-lasting effects
H412	Harmful to aquatic life with long-lasting effects
H413	May cause long-lasting harmful effects to aquatic life
H420	Harms public health and the environment by destroying ozone in the upper atmosphere

[ CAS No. 1228014-10-5 ] {[proInfo.proName]}

Quality Control of [ 1228014-10-5 ]

Related Doc. of [ 1228014-10-5 ]

Product Details of [ 1228014-10-5 ]

Calculated chemistry of [ 1228014-10-5 ]

Physicochemical Properties

Pharmacokinetics

Lipophilicity

Druglikeness

Water Solubility

Medicinal Chemistry

Safety of [ 1228014-10-5 ]

Application In Synthesis of [ 1228014-10-5 ]

[ 1228014-10-5 ] Synthesis Path-Upstream 1~3

[ 1228014-10-5 ] Synthesis Path-Downstream 1~15

Related Functional Groups of [ 1228014-10-5 ]

Organoboron

Esters

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Related Functional Groups of
[ 1228014-10-5 ]